Physician

Internal Medicine

Dr. John D. Reeves, MD

John Reeves works in the field of Internal Medicine. He went to medical school at Eastern Virginia Medical School. John D. Reeves, MD is a published doctor and has 46 publications published. The lastest was: 'CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages.'

Publications

DC-SIGN interactions with human immunodeficiency virus: virus binding and transfer are dissociable functions.
Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat.
Chemokine inhibition of HIV infection.
Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and ...
Coreceptor ligand inhibition of fetal brain cell infection by HIV type 1.
CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages.
A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4.
Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines.
CD4-independent infection by human immunodeficiency virus type 2 strain ROD/B: the role of the N-terminal domain of CXCR-4 in fusion and entry.
CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry.
Urine and plasma catecholamine and cortisol concentrations after myocardial revascularization. Modulation by continuous sedation. Multicenter Study of Perioperative Is...
The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold ...
Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry.
The risk of myocardial ischemia in patients receiving desflurane versus sufentanil anesthesia for coronary artery bypass graft surgery. The S.P.I. Research Group.
Drug Resistance and Viral Tropism in HIV-1 Subtype C-Infected Patients in KwaZulu-Natal, South Africa: Implications for Future Treatment Options.
Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.
Lack of clinical AIDS in SIV-infected sooty mangabeys with significant CD4+ T cell loss is associated with double-negative T cells.
Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.
Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance.
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A...
Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays.
Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein.
Virally induced CD4+ T cell depletion is not sufficient to induce AIDS in a natural host.
Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.
Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion.
A simian immunodeficiency virus V3 loop mutant that does not efficiently use CCR5 or common alternative coreceptors is moderately attenuated in vivo.
Cellular entry of HIV: Evaluation of therapeutic targets.
Functional impact of HIV coreceptor-binding site mutations.
Emerging drug targets for antiretroviral therapy.
Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.
Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.
Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity.
Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.
Amino acid 324 in the simian immunodeficiency virus SIVmac V3 loop can confer CD4 independence and modulate the interaction with CCR5 and alternative coreceptors.
Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry.
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.
Evolution of coreceptor use and CD4-independence in envelope clones derived from SIVsm-infected macaques.
Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor o...
Human Leydig cells are productively infected by some HIV-2 and SIV strains but not by HIV-1.
DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells.
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Human immunodeficiency virus type 2.
Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.

Schools

Wright State University Main Campus
Kettering Med Center
Ea Va Grad School Med
St John Hospital and Med Center

Doctors Specialties

Internal Medicine

Accepted Insurances

Education

Eastern Virginia Medical School
St John Hospital and Medical Center
Wright State University Boonshoft School of Medicine

Drug Facts

NPI NUMBER		1396737540
NPPES Provider LastName		REEVES
NPPES Provider FirstName		JOHN
NPPES Provider ZIPCode		711033908
NPPES Provider State		LA
Specialty Description		Internal Medicine
Total Claim Count		588.0
Distinct Opioid Count		2.0
Opioid Claim Count		157.0
Percent Opioid Claims		26.7

Helpful Reviews

Give Anonymous Review

Medicare Facts

National Provider Identifier [NPI]	1396737540
Last Name Of The Provider	REEVES
First Name Of The Provider	JOHN
View All

Similar Doctors

	Dr. Amer Arshad, MD This Doctor is OpenDoctor Recommended.
	Dr. Samer S. Obri, MD This Doctor is OpenDoctor Recommended.
	Dr. Paul E. Brose, MD This Doctor is OpenDoctor Recommended.
	Dr. Stavros R. Karatsoridis, DO This Doctor is OpenDoctor Recommended.
	Dr. Amjad Shidyak, MD This Doctor is OpenDoctor Recommended.
	Dr. Peter C. Lenhart, MD This Doctor is OpenDoctor Recommended.
	Dr. Husam B. Semaan, MD
	Kyle Mills